Renovascular Disease and Renal Artery Revascularization

46.1Treat the syndrome, not the picture

Renovascular disease is not an angiographic diagnosis that obligates repair. It is a clinical syndrome in which renal arterial obstruction, kidney function, blood pressure behavior, cardiac decompensation, and systemic atherosclerotic risk intersect. In adults, atherosclerosis accounts for roughly 90% of renal-artery obstruction, so an older patient with ostial renal-artery stenosis, hypertension, chronic kidney disease, and other vascular disease should be approached as having atherosclerotic renovascular disease unless the phenotype argues otherwise Atherosclerotic renal artery 2011. That presumption should not become diagnostic laziness. Fibromuscular dysplasia, vasculitis, neurofibromatosis, congenital bands, extrinsic compression, and radiation injury remain important alternative causes, particularly when the patient is younger, female, pediatric, lacks systemic atherosclerotic disease, or has mid- or distal-vessel involvement rather than typical ostial disease.

The first decision for the surgeon is not whether the artery looks narrow, but whether the stenosis plausibly explains a treatable clinical problem. Atherosclerotic renal-artery stenosis may present as renovascular hypertension, ischemic nephropathy, or both, with substantial overlap; the physiology is driven in part by renin-angiotensin-aldosterone activation and sodium retention Atherosclerotic renal artery 2006. A practical consultation note should therefore state the clinical indication in one sentence: preservation of renal function, treatment of truly resistant hypertension, prevention of recurrent flash pulmonary edema, or no current indication for revascularization. This framing prevents the common error of escalating from “stenosis present” to “stent indicated” without proving that the patient has a syndrome likely to benefit.

Assessment should be directed at findings that will change management. The history should establish the trajectory of kidney function, the number and adequacy of antihypertensive agents, the presence of pulmonary edema episodes, and the competing likelihood of intrinsic renal disease. Documentation should identify whether renal function has been stable or rapidly declining, whether hypertension is resistant despite optimal medical therapy, and whether pulmonary edema has occurred in a pattern compatible with renovascular cardiac destabilization When Revascularization May 2024. When the patient resembles those enrolled in randomized trials of atherosclerotic renal-artery stenosis, the default treatment is optimized medical therapy; when the patient has flash pulmonary edema, rapidly declining renal function, or truly resistant hypertension with hemodynamically confirmed stenosis, selective revascularization becomes a reasonable multidisciplinary discussion.

Imaging should answer a management question, not merely decorate the chart. Duplex ultrasound is useful for surveillance and for following known disease over time, but cross-sectional imaging is often needed when anatomic planning will influence intervention. Renal-artery MRI can provide non-contrast and contrast-enhanced angiographic assessment without iodinated contrast, making it a practical alternative when iodinated CTA is undesirable and local renal-MRA expertise is reliable Magnetic Resonance Imaging 2024. The trainee should learn to read the report with the intended treatment in mind: ostial versus mid-vessel disease, bilateral involvement, solitary functioning kidney, renal size, adjacent aortic plaque, and whether the stenosis is being called severe enough to explain the syndrome Atherosclerotic renal artery 2011.

When resistant hypertension is the dominant syndrome, patient selection must be particularly disciplined. A covered-stent registry in adults with severe atherosclerotic renal-artery stenosis of at least 80% and resistant hypertension on at least three antihypertensive agents reported 94.3% primary patency at 9 months and a mean systolic blood pressure reduction of 15.7 mm Hg De Novo Atherosclerotic 2024. The same cohort reported a 36-month clinically driven target-lesion revascularization rate of 7.3% and major adverse events in 8.8% of treated subjects. These data support a careful conversation in a selected resistant-hypertension phenotype, but they should not be generalized into routine stenting for every severe stenosis because the evidence is registry-based, small, and device-focused rather than a broad event-reduction trial.

46.2Medical therapy and trial boundary

Optimized medical therapy is the default treatment for unselected atherosclerotic renal-artery stenosis. The reason is not therapeutic nihilism; it is that the randomized evidence has repeatedly failed to show that routine revascularization improves the outcomes patients care about most. In CORAL, adults with atherosclerotic renal-artery stenosis and hypertension or chronic kidney disease were randomized to stenting plus multifactorial medical therapy versus medical therapy alone. At a median follow-up of 43 months, the primary composite of cardiovascular and renal events occurred in 35.1% of the stent group and 35.8% of the medical-therapy group, with a hazard ratio of 0.94 and a 95% confidence interval from 0.76 to 1.17 Stenting medical therapy 2014. For a patient who fits the CORAL population, renal-artery stenting should not be offered as a procedure to prevent that composite endpoint.

The blood pressure signal in unselected trial populations is real but small. In CORAL, stenting produced a statistically consistent mean systolic blood pressure difference of approximately -2.3 mm Hg compared with medical therapy alone, but that modest improvement did not translate into fewer cardiovascular or renal events Stenting medical therapy 2014. Longitudinal quality-of-life analysis from the CORAL cohort similarly did not show a sustained quality-of-life advantage from adding stenting to medical therapy Quality life effects 2025. The clinical implication is straightforward: do not promise the patient a meaningful symptomatic or prognostic gain from stenting when the patient has stable kidney function, no pulmonary edema syndrome, and hypertension that can be managed medically.

Systematic reviews reinforce this boundary. A Cochrane review of eight trials including 2222 hypertensive patients with atherosclerotic renal-artery stenosis concluded that balloon angioplasty, with or without stenting, was not clearly superior to medical therapy for blood pressure or renal outcomes, although it produced a small reduction in diastolic blood pressure and antihypertensive drug requirement Balloon angioplasty stenting 2014. A later systematic review of nine randomized trials including 2309 patients found lower odds of refractory hypertension with percutaneous transluminal renal angioplasty plus best medical therapy, but no significant differences in stroke, cardiac, renal, or all-cause mortality endpoints Use percutaneous transluminal 2021. A 2015 pooled evidence update likewise concluded that adding revascularization to optimal medical therapy did not reduce clinical events or mortality in unselected atherosclerotic renovascular disease Renal artery stenosis: intervention vs medical 2015.

The trial boundary matters at the bedside. CORAL required stable renal function and absence of nephrotic-range proteinuria, so it should be applied to comparable patients and extended cautiously to those with syndromes under-represented in the randomized cohorts Stenting medical therapy 2014. RADAR was also designed as a multicentre prospective randomized comparison of best medical treatment alone versus best medical treatment plus renal-artery stenting, with renal-function change at one-year follow-up as the primary endpoint; its published results did not demonstrate a renal-function or hard-event advantage of stenting, but the trial enrolled fewer patients than planned and is best read as directionally supportive of the CORAL and ASTRAL experience rather than as a standalone mandate Randomized multi-center prospective 2017 · RADAR randomised multi-centre 2009. For the resident, the practical lesson is to know exactly which patient is being compared with the randomized evidence and which patient is not.

Medical therapy must be active and longitudinal. Because renovascular hypertension reflects RAAS activation and sodium retention, ACE inhibitors or ARBs are often physiologically appropriate, but bilateral stenosis or a solitary functioning kidney requires special caution and creatinine monitoring after initiation or dose escalation Atherosclerotic renal artery 2006. Risk-factor treatment should be handled as systemic vascular secondary prevention, not as kidney-only management: statin therapy, antiplatelet therapy when otherwise indicated, blood-pressure control, glycemic control, and smoking cessation belong in the same plan as renal duplex surveillance and nephrology follow-up ACC/AHA 2024. The surgeon should not let a “no stent” decision become a “no treatment” decision; atherosclerotic renal-artery stenosis is a marker of diffuse vascular risk Atherosclerotic renal artery 2011.

There remains a narrow but important group in whom revascularization is clinically sensible despite the randomized trial boundary. Patients with flash pulmonary edema, rapidly declining renal function, or truly resistant hypertension despite optimal medical therapy and hemodynamically confirmed stenosis are the group in whom selective intervention may be appropriate When Revascularization May 2024. A prospective two-center cohort of consecutive high-risk patients undergoing renal-artery stenting reported clinical benefit signals in patients with rapidly declining renal function or flash pulmonary edema, supporting referral of these CORAL-excluded phenotypes for multidisciplinary review Renal Artery Stenting 2022. Pharmacologic adjuncts to renal stenting, including mitochondrial-protection strategies such as elamipretide, remain investigational and should not be offered outside clinical-trial settings Phase Clinical Trial 2017.

46.3Technique follows indication

The operative plan follows the indication, not the other way around. In atherosclerotic renal-artery stenosis, disease usually involves the ostium and proximal third of the renal artery and often includes the adjacent aorta; advanced cases may also have segmental and diffuse intrarenal atherosclerosis Atherosclerotic renal artery 2011. This anatomy explains why an apparently simple renal lesion can be technically unforgiving. The lesion is frequently an aorto-ostial plaque shoulder rather than an isolated tubular narrowing, and a procedure that fails to treat the ostium adequately risks leaving the hemodynamic problem behind. Conversely, mid- or distal-vessel disease should make the surgeon reconsider the diagnosis and look for fibromuscular dysplasia or inflammatory disease rather than forcing an atherosclerotic template onto the case.

The pre-procedural plan should explicitly connect the target lesion to the clinical objective. If the objective is blood pressure control, the patient should have truly resistant hypertension despite appropriate medical therapy and severe, hemodynamically meaningful atherosclerotic renal-artery stenosis When Revascularization May 2024. If the objective is preservation of kidney function, the record should show a trajectory of rapid decline rather than chronic stable renal impairment of uncertain cause. If the objective is prevention of pulmonary edema, the episodes should be clearly documented and clinically compatible with renovascular destabilization Renal Artery Stenting 2022. A technically successful stent placed for a poorly defined indication is not a successful vascular operation; it is an anatomic intervention without a durable clinical endpoint Atherosclerotic renal artery 2006.

Baseline risk stratification should include factors that make benefit less predictable. Atherosclerotic renal-artery stenosis is associated with progressive loss of renal mass and function, with renal atrophy reported in roughly 21% of patients with 60% obstruction in a renovascular hypertension subgroup Atherosclerotic renal artery 2011. Advanced renal atrophy and diffuse intrarenal atherosclerosis reduce the plausibility that restoring main renal-artery caliber will restore renal function. Elevated serum uric acid was associated with worse renal and blood-pressure outcomes after renal-artery stenting in a renal revascularization registry, making it a reasonable baseline variable to document as a candidate prognostic marker, while recognizing that it is not a randomized selection criterion Impact Serum Uric 2019.

Device choice should be discussed in the context of the lesion and the strength of evidence. For the selected severe ostial atherosclerotic stenosis with resistant hypertension, covered-stent treatment has registry support: the ARTISAN experience reported high 9-month primary patency and meaningful mean systolic blood pressure reduction, with late clinically driven target-lesion revascularization that must be included in consent De Novo Atherosclerotic 2024. That evidence is useful for counseling but limited by single-arm design and small cohort size. A good resident should be able to say both parts in the same sentence: the device may be reasonable for a carefully selected resistant-hypertension phenotype, and the data do not overturn the randomized trial conclusion against routine stenting in unselected atherosclerotic renal-artery stenosis Stenting medical therapy 2014.

Transplant renal-artery stenosis is a distinct technical and surveillance problem. Contemporary systematic reviews identify recipient cardiovascular comorbidity, delayed graft function, surgical anastomotic factors, and donor age among consistent risk markers, supporting intensified surveillance in higher-risk transplant recipients Predictors transplant renal 2026. A separate systematic review estimates transplant renal-artery stenosis prevalence at several percent globally, with substantial heterogeneity driven by geography and stenosis definitions Global prevalence contributing 2024. In practice, transplant cases should be evaluated with attention to anastomotic configuration, graft function, and center-specific imaging quality; the clinical question is preservation of graft function and blood pressure control, not treatment of a native ostial plaque phenotype.

46.4Clinical integration, follow-up, and evidence boundaries

Follow-up after a diagnosis of atherosclerotic renal-artery stenosis should be planned even when no intervention is performed. In a duplex-surveillance cohort of 170 patients with atherosclerotic renal-artery stenosis, the cumulative 5-year incidence of stenosis progression reached approximately 51% Atherosclerotic renal artery 2011. That figure justifies longitudinal surveillance rather than a one-time diagnostic declaration. A practical schedule should include at least annual renal duplex in patients with documented disease and ongoing risk factors, with earlier reassessment when blood pressure control deteriorates, renal function declines, or pulmonary edema occurs When Revascularization May 2024.

Surveillance findings should be interpreted with the clinical course. Progression on duplex is important, but it does not automatically create an indication for stenting; it becomes meaningful when paired with a management-changing syndrome such as rapidly declining kidney function, truly resistant hypertension, or flash pulmonary edema When Revascularization May 2024. Similarly, stable duplex findings do not end the surgeon’s responsibility if the patient’s systemic vascular risk is poorly controlled. Atherosclerotic renal-artery stenosis is associated with coronary event risk and progressive renal mass loss, so each follow-up visit should revisit cardiovascular prevention, blood pressure regimen, renal function trajectory, and whether the working diagnosis still fits the anatomy and clinical pattern ACC/AHA 2024 · Atherosclerotic renal artery 2011.

After renal-artery intervention, surveillance has two purposes: detecting lesion failure and judging whether the clinical endpoint was achieved. The operative note and follow-up plan should state the preoperative indication, technical result, intended clinical endpoint, and the first surveillance interval. Blood pressure, medication burden, serum creatinine trajectory, and recurrent pulmonary edema are more important than patency alone because the operation was performed to treat a clinical syndrome Atherosclerotic renal artery 2006. Late failure is not rare enough to ignore; in the covered-stent resistant-hypertension cohort, clinically driven target-lesion revascularization was 7.3% at three-year follow-up De Novo Atherosclerotic 2024. A surveillance report that suggests restenosis should trigger a return to the indication checklist before any repeat intervention When Revascularization May 2024.

Complication counseling should be specific. In the Cochrane review of renal angioplasty with or without stenting, procedural complications included groin hematoma in roughly 6.5%, femoral pseudoaneurysm in less than 1%, renal-artery or kidney perforation/dissection in about 2.5%, and peri-procedural death in approximately 0.4% Balloon angioplasty stenting 2014. These older aggregate rates may not match a contemporary high-volume practice exactly, but they are useful benchmarks for consent and for deciding whether an institution’s threshold for intervention is appropriately selective. The resident should learn to present these risks plainly, especially when the expected benefit is a small blood pressure change rather than prevention of a clear high-risk syndrome Stenting medical therapy 2014.

Long-term care should not focus narrowly on the stent. In a large multicenter renal-stenting registry, long-term mortality in atherosclerotic renovascular disease was driven principally by cardiovascular causes rather than renal failure Long-Term Outcomes Causes 2016. That finding should shape survivorship care: the follow-up visit is an opportunity to intensify systemic vascular prevention, coordinate nephrology and hypertension management, and reassess whether new symptoms represent progression of diffuse atherosclerosis rather than isolated renal restenosis ACC/AHA 2024. For transplant renal-artery stenosis, follow-up should be risk-stratified because prevalence estimates vary and risk markers differ across centers; donor age, delayed graft function, anastomotic factors, and recipient cardiovascular comorbidity should influence how aggressively graft dysfunction or hypertension prompts imaging Predictors transplant renal 2026 · Global prevalence contributing 2024.